Effects of rosuvastatin treatment on coronary artery ectasia in different patient age groups

Chenghui Fan, Ying Hao, Yonghua Liu, Xiaolin Li, Zhenhao Huang, Yu Luo, Ruilin LiResearch Square 2020 · DOI

Abstract

Background: This study investigated the relationship between coronary artery ectasia (CAE) and serum levels of high-sensitivity C-reactive protein (Hs-CRP) to test the hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy in CAE.

Method: A prospective analysis was conducted on 217 patients with CAE and 73 healthy controls (NC Group). Participants were grouped by age: CAE-A (≤50 years), CAE-B (50–70 years), and CAE-C (>70 years). All CAE patients received 10 mg of rosuvastatin nightly for six months.

Results: Inflammatory markers were significantly higher in CAE patients than in the NC Group, with the highest levels observed in the youngest group (CAE-A). Following treatment, the CAE-A group showed the most significant reduction in Hs-CRP and IL-6 levels, while the CAE-C group showed negligible change.

Conclusions: Anti-inflammatory therapy using rosuvastatin was more effective in younger CAE patients, indicating the need for early statin therapy.

Introduction

Coronary artery ectasia (CAE) is a cardiovascular abnormality characterized by the dilation of coronary artery segments to at least 1.5 times their normal diameter. While often associated with atherosclerosis, its precise etiology remains elusive, with systemic inflammation identified as a primary pathogenic factor. Currently, there are no standardized clinical guidelines for CAE treatment. This study explores whether patient age influences inflammatory status and the subsequent response to statin therapy, specifically rosuvastatin.

Methods

The researchers analyzed a cohort of 217 CAE patients and 73 healthy controls across three medical centers. CAE was confirmed via coronary angiography. Patients were stratified into three age-based groups:

  • CAE-A: ≤50 years (n=60)
  • CAE-B: 50–70 years (n=83)
  • CAE-C: >70 years (n=74)

All patients in the CAE groups received 10 mg of rosuvastatin nightly for six months. The primary biomarkers measured were high-sensitivity C-reactive protein (Hs-CRP) and interleukin-6 (IL-6).

Results and Key Insights

The Inflammatory Profile of CAE

Baseline data revealed that CAE patients possess significantly higher levels of systemic inflammation compared to healthy individuals. Interestingly, a "young and inflamed" paradox was observed: the youngest patients (≤50 years) exhibited the highest baseline inflammatory markers (Hs-CRP: 32.3 mg/L vs. 16.9 mg/L in controls). This suggests that CAE in younger populations may be driven by a more active inflammatory state.

Multivariate logistic regression confirmed that both Hs-CRP and IL-6 are independent predictors of CAE, with Hs-CRP showing a strong association (OR = 1.782).

Multivariate logistic regression analysis identifying independent predictors of CAE.

Age-Dependent Treatment Response

The efficacy of rosuvastatin treatment followed a clear age gradient. The youngest cohort (CAE-A) experienced the most dramatic improvements, with Hs-CRP levels dropping from 32.3 to 17.5 mg/L ($p=0.0001$) and IL-6 dropping from 12.3 to 6.4 pg/dL ($p=0.021$). In contrast, the oldest group (CAE-C) showed no statistically significant change in inflammatory markers.

Comparison of inflammatory markers before and after 6 months of rosuvastatin treatment across age groups.

Discussion

The findings suggest that younger individuals may be more sensitive to the anti-inflammatory effects of statins, potentially due to higher basal metabolic rates in lipid synthesis and degradation. The lack of significant response in older patients might reflect a more chronic, less reversible inflammatory state or different underlying disease mechanisms.

Limitations

The study is limited by its relatively small sample size for a multi-center trial and the use of angiography rather than more precise imaging modalities like Intravascular Ultrasound (IVUS). Future research should investigate the specific biological pathways that account for this age-dependent sensitivity.

Conclusion

Early intervention with rosuvastatin is highly effective in reducing systemic inflammation in younger patients with coronary artery ectasia. These results underscore the importance of early diagnosis and the prompt initiation of statin therapy to manage the disease effectively.

Summary updated

Abstract

<title>Abstract</title> Background: This study investigated the relationship between coronary artery ectasia (CAE) and serum levels of high-sensitivity C-reactive protein (Hs-CRP) to test our hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy in CAE. Method: We conducted a prospective analysis of 217 patients with CAE treated at the Department of Cardiology, Shanghai East Hospital, Shanghai East Hospital (Ji'an Campus), Cardiovascular Medicine of Baoshan People’s Hospital of Yunnan Province, from January 1, 2015, to July 30, 2019. Baseline data of patients, including sex, age, hypertension, hyperlipidemia, and diabetes, were collected from patient medical records. Study participants were grouped by age: CAE-A (age ≤50 years); CAE-B (50 years 70). Results: All CAE patients received oral rosuvastatin therapy (10 mg, QN quaque night) and maintained good follow-up, with a loss rate of 0.0% at the 6-month follow-up. The control group (NC Group, n = 73, with normal coronary arteries) received regular symptom-relieving treatments. Among these four groups, the inflammatory markers were significantly higher in patients with CAE than in the NC Group. The inflammatory markers in the CAE-A group were higher than in the CAE-B group, which were higher than the CAE-C group. Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in Hs-CRP and interleukin-6 levels in the CAE-A group than the CAE-B group, which, again, were higher than the CAE-C group. Conclusions: Anti-inflammatory therapy using rosuvastatin was more effective in younger CAE patients, indicating the need for early statin therapy in CAE patients.
BibTeX
@inproceedings{fan2020effects,
  author = {Chenghui Fan and Ying Hao and Yonghua Liu and Xiaolin Li and Zhenhao Huang and Yu Luo and Ruilin Li},
  title = {{Effects of rosuvastatin treatment on coronary artery ectasia in different patient age groups}},
  booktitle = {Research Square},
  year = {2020},
  doi = {10.21203/rs.3.rs-21391/v1},
}
Figure